首页|健脾润肺丸对肺结核患者β-CAR、VEGF、IFN-γ、IL-17水平的影响

健脾润肺丸对肺结核患者β-CAR、VEGF、IFN-γ、IL-17水平的影响

扫码查看
目的 研究健脾润肺丸对肺结核患者 β-胡萝卜素(β-CAR)、血管内皮生长因子(VEGF)、干扰素-γ(IFN-γ)、白介素-17(IL-17)水平的影响.方法 以2020年1月至2023年4月张家口市肺科医院收治的肺结核患者120例为研究对象,采用随机数字表法分为进行常规治疗的常规组(60例)和联合健脾润肺丸治疗的联合组(60例),两组均治疗90 d.比较两组疗效、临床症状、体征改善情况及血清细胞因子水平(β-CAR、VEGF、IFN-γ、IL-17)、免疫功能(CD3+、CD4+、CD8+、CD4+/CD8+)、肺功能[用力呼气量(FEV1)、用力肺活量(FVC)、FEV1/FVC].结果 治疗90 d后,联合组总有效率高于常规组,差异有统计学意义(P<0.05).联合组咳嗽、咳痰、胸憋气短、咯血胸痛症消失时间、痰涂片抗酸杆菌连续3次阴转时间及肺部胸片病灶缩小时间均短于常规组,差异有统计学意义(P<0.05).两组治疗90 d后血清β-CAR、VEGF、IL-17水平、外周血CD8+百分比低于治疗前,且联合组低于常规组,差异有统计学意义(P<0.05);血清IFN-γ水平、外周血CD3+、CD4+百分比及CD4+/CD8+、FEV1、FVC、FEV1/FVC高于治疗前,且联合组高于常规组,差异有统计学意义(P<0.05).结论 健脾润肺丸可改善肺结核患者血清β-CAR、VEGF、IFN-γ、IL-17水平及免疫功能、肺功能,促进患者临床症状、体征改善,具有较好的治疗效果.
Effects of Jianpi Runfei Pills on levels of β-CAR,VEGF,IFN-γ,and IL-17 in patients with pulmonary tuberculosis
Objective To study the effects of Jianpi Runfei Pills on levels of β-carotene (β-CAR),vascular endothelial growth factor (VEGF),interferon-γ (IFN-γ),and interleukin-17 (IL-17) in patients with pulmonary tuberculosis.Methods A total of 120 patients with pulmonary tuberculosis admitted to Zhangjiakou Pulmonary Hospital from January 2020 to April 2023 were divided into the conventional group (60 cases) and the combined group (60 cases) by random number table method.Both groups were treated for 90 d.The study aimed to compare the efficacy,improvement in clinical symptoms,and signs,serum cytokine levels (β-CAR,VEGF,IFN-γ,IL-17),immune function (CD3+,CD4+,CD8+,CD4+/CD8+),lung function[forced expiratory volume (FEV1),forced vital capacity (FVC),FEV1/FVC]between two groups.Results After 90 days of treatment,the total effective rate of the combined group was higher than that of the conventional group,with statistical significance (P<0.05).In comparison to the conventional group,the combined group showed shorter duration of cough,sputum,short chest suffrage,disappearance time of hemoptysis chest pain,three consecutive negative rotations of acid-fast bacilli in sputum smear,and lung film focal shrinkage time,all with statistical significance (P<0.05).After 90 days of treatment,the levels of serum β-CAR,VEGF,IL-17 and the percentage of peripheral blood CD8+in 2 groups were lower than before treatment,and the combined group was lower than the conventional group,with statistical significance (P<0.05).The levels of serum IFN-γ,percentages of peripheral blood CD3+,CD4+and CD4+/CD8+,forced expiratory volume (FEV1),forced vital capacity (FVC),and FEV1/FVC increased compared to before treatment,with the combined group showing higher levels than the conventional group,all with statistical significance (P<0.05).Conclusion Jianpi Runfei pills could improve the levels of serum β-CAR,VEGF,IFN-γ,and IL-17,enhance immune function and lung function in patients with pulmonary tuberculosis.They also promote the improvement of clinical symptoms and signs in patients,showing a positive therapeutic effect.

TuberculosisSpleen-invigorating lung pillβ-CARVEGFIFN-γIL-17

张丽红、张建楠、朱云、吴敏、韩燕斌、彭丽欢

展开 >

张家口市肺科医院内三科,河北,张家口 075400

怀来县医院儿科,河北,张家口 075400

肺结核 健脾润肺丸 β-胡萝卜素 血管内皮生长因子 干扰素-γ 白介素-17

张家口市重点研发计划项目

2322137D

2024

分子诊断与治疗杂志
中山大学

分子诊断与治疗杂志

CSTPCD
影响因子:0.65
ISSN:1674-6929
年,卷(期):2024.16(8)
  • 1